Drugs in ATC Class P02CX

Up to Top Level ATC Classes

Up to P - Antiparasitic products, insecticides and repellents

Up to P02 - ANTHELMINTICS

Up to P02C - ANTINEMATODAL AGENTS

Drugs in ATC Class: P02CX - Other antinematodals

Tradename	Generic Name
MOXIDECTIN	moxidectin
POVAN	pyrvinium pamoate

P02CX Market Analysis and Financial Projection

The market for ATC Class P02CX ("Other antinematodals") demonstrates niche therapeutic importance amid evolving parasitic infection challenges. This class includes drugs like pyrvinium, bephenium hydroxynaphthoate, and moxidectin, which address nematode infections when first-line treatments fail or resistance emerges[11][14].

---

Market Dynamics

Growth Drivers

1. Rising Helminth Infections
   Soil-transmitted helminths infect 1.5 billion globally, with P02CX drugs serving as alternatives in resistant cases[8][14].
2. Veterinary Applications
   Moxidectin (P02CX03) is widely used in veterinary medicine for broad-spectrum parasite control, with patented high-concentration formulations enhancing efficacy[4][13].
3. Repurposing Opportunities
   Pyrvinium (P02CX01) is under investigation for anticancer applications, with patents filed for its use in Wnt pathway inhibition[16][17].

Market Size & Projections

• Human Health: The global anthelmintic market (valued at $1B in 2022) is projected to grow at 3.8% CAGR, reaching $1.5B by 2032[3][8].
• Veterinary Sector: Moxidectin-driven products dominate livestock care, with parasiticidal collars and spot-on formulations securing patent protections[4][13].

Market Segment	2022 Value	2032 Projection	CAGR
Human Anthelmintics	$1B	$1.5B	3.8%
Veterinary Antiparasitics	$2.75B*	$3.85B*	3.8%

*Includes non-P02CX products[10]

---

Patent Landscape

Key Innovations

1. Formulation Patents

   • Boehringer Ingelheim’s high-concentration fipronil/moxidectin formulations (US10864193) extend efficacy against ectoparasites[4].
   • Pyrvinium pamoate patents (WO-2019126739-A1) explore oncology applications[16].

2. Resistance Mitigation
   Combination therapies (e.g., moxidectin + insect growth regulators) aim to counter nematode resistance[4][13].

Generic Competition

• Bephenium hydroxynaphthoate and pyrvinium face genericization, with no recent NME patents[12][15].
• Moxidectin retains exclusivity in veterinary applications through novel delivery systems[13].

---

P02CX Drug Utilization

Drug	Primary Use	Market Status	Key Players
Pyrvinium (P02CX01)	Pinworm infections	Generic; niche human use[7]	Reese Pharmaceutical[8]
Bephenium (P02CX02)	Roundworm/hookworm infections	Low-cost generic[12]	Sun Pharma, Cipla[8][10]
Moxidectin (P02CX03)	Veterinary parasites	Patent-protected formulations[4][13]	Zoetis, Boehringer[10]

---

Challenges & Opportunities

Barriers

• Resistance Concerns: Overuse of benzimidazoles (e.g., albendazole) pressures P02CX drugs as second-line options[8][14].
• Regulatory Hurdles: Strict ATC classification guidelines delay new entrants[6][14].

Strategic Opportunities

1. Combo Therapies: Patent-protected formulations blending P02CX drugs with IGRs[4].
2. Emerging Markets: Asia-Pacific’s parasitic disease burden drives demand[8][10].
3. Drug Repurposing: Pyrvinium’s anticancer potential opens new revenue streams[16][17].

---

Future Outlook

While P02CX drugs represent a small segment (~2.4% of antiparasitic sales)[1][9], their role in addressing resistance and zoonotic diseases ensures sustained relevance. Innovation in veterinary applications and repurposing efforts will likely outweigh stagnating human-use markets, with moxidectin and pyrvinium derivatives leading growth through 2032[4][13][16].

References

1. https://www.fhi.no/contentassets/00c2c40952bb4c3da07216b656b72a7b/rapport-legemiddelstatistikk-2020.pdf
2. https://patents.google.com/patent/WO2013075199A1/pt
3. https://www.prnewswire.com/news-releases/anthelmintic-drugs-market-to-reach-1-5-billion-globally-by-2032-at-3-8-cagr-allied-market-research-302005943.html
4. https://patents.justia.com/patent/10864193
5. https://www.drugpatentwatch.com/p/atc-class/P02CA
6. https://atcddd.fhi.no/filearchive/publications/2025_guidelines__final_web.pdf
7. https://go.drugbank.com/drugs/DB06816
8. https://www.alliedmarketresearch.com/anthelmintic-drugs-market-A11501
9. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2018/reseptregisteret-2013_2017-temadel-om-legemidler-og-eldre.pdf
10. https://www.zionmarketresearch.com/report/anthelmintic-drugs-market
11. https://en.wikipedia.org/wiki/ATC_code_P02
12. https://medtigo.com/drug/bephenium-hydroxynaphthoate/
13. https://www.ams.usda.gov/sites/default/files/media/Mox%20Technical%20Advisory%20Panel%20Report%20(2003).pdf
14. https://atcddd.fhi.no/atc_ddd_index/?code=P02CX&showdescription=yes
15. https://pubchem.ncbi.nlm.nih.gov/compound/Pyrvinium
16. https://pubchem.ncbi.nlm.nih.gov/patent/WO-2019126739-A1
17. https://patents.google.com/patent/US20090099062A1/en